Navigation Links
Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
Date:3/1/2012

VANCOUVER, British Columbia, March 1, 2012 /PRNewswire/ -- Enox Biopharma, Inc. (VANCOUVER, BC.) CEO, John C. Rewcastle, Ph.D., will present at the IN360 Investment in Innovation Conference on Thursday, March 1 at 10:35 AM EST. The conference is being held at the Ritz Carlton Hotel in Orlando.

The IN360 is the newest iteration of the successful IN3 meeting series, hosted by Elsevier. It is a medical device technology forum and networking meeting. The foundation of the meeting is presentations from emerging companies like Enox Biopharma to audiences principally composed of larger medical device manufacturers and venture capitalists.

Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. This innovative technology is a potential solution to one of the most significant burdens on medical systems worldwide: hospital acquired infections.

"In the United States alone, it is estimated that $30-45 billion dollars per year are spent due to hospital acquired infections," said Enox CEO John Rewcastle. "Enox is uniquely positioned to address this problem by inhibiting the formation of infections seeded when a medical device such as a catheter is inserted into the body. With nitric oxide as the mechanism of action, devices incorporating our technology will not have issues such as non-effectiveness or antibiotic resistance as do competitive products."

"The IN360 meeting is a uniquely effective environment provide exposure and constructive interaction between emerging and established medical device companies," continued Rewcastle. "Enox will be especially attractive to potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. NO is also an effective vasodilator which can lead to accelerated wound healing. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Enox Biopharma, Inc. Expands Its Technology to Cover the Wound Care Market
2. PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015
3. Enox Biopharma, Inc. Appoints Dr. John Rewcastle as CEO
4. Sinobiopharma, Inc. Appoints New Director of Marketing
5. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
6. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
7. Regeneron Announces March 2012 Investor Conference Presentations
8. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
9. OncoSec to Present at 10th Annual BioPartnering North America
10. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
11. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Global demand for enzymes is forecast to grow ... billion.  This market includes enzymes used in industrial ... animal feed, and other markets) and specialty applications ... beverages will remain the largest market for enzymes, ... containing enzymes in developing regions.  These and other ...
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf ... join the faculty of the University of North Carolina Kenan-Flagler Business School ... and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):